Yuan, Bo
Neira, Juanita
Pehlivan, Davut
Santiago-Sim, Teresa
Song, Xiaofei
Rosenfeld, Jill
Posey, Jennifer E.
Patel, Vipulkumar
Jin, Weihong
Adam, Margaret P.
Baple, Emma L.
Dean, John
Fong, Chin-To
Hickey, Scott E.
Hudgins, Louanne
Leon, Eyby
Madan-Khetarpal, Suneeta
Rawlins, Lettie
Rustad, Cecilie F.
Stray-Pedersen, Asbjørg
Tveten, Kristian
Wenger, Olivia
Diaz, Jullianne
Jenkins, Laura
Martin, Laura
McGuire, Marianne
Pietryga, Marguerite
Ramsdell, Linda
Slattery, Leah
Abid, Farida
Bertuch, Alison A.
Grange, Dorothy
Immken, LaDonna
Schaaf, Christian P.
Van Esch, Hilde
Bi, Weimin
Cheung, Sau Wai
Breman, Amy M.
Smith, Janice L.
Shaw, Chad
Crosby, Andrew H.
Eng, Christine
Yang, Yaping
Lupski, James R.
Xiao, Rui
Liu, Pengfei
Article History
Received: 23 December 2017
Accepted: 1 June 2018
First Online: 30 August 2018
Disclosure
: Baylor College of Medicine (BCM) and Miraca Holdings Inc. have formed a joint venture with shared ownership and governance of Baylor Genetics (BG), formerly the Baylor Miraca Genetics Laboratories (BMGL), which performs chromosomal microarray analysis and clinical exome sequencing. JR, VP, WJ, CS, WB, SWC, AMB, JLS, CE, YY, RX, and PL are employees of BCM and derive support through a professional services agreement with the BG. JRL serves on the Scientific Advisory Board of the BG. JRL has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, has stock options in Lasergen, Inc., and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The other authors declare no conflict of interest. All authors read and approved the final manuscript.